Productivity and Cost-Effectiveness of Initiative for Decentralized Cancer Care in Region Uppsala, Sweden
Author(s)
Martina Aldvén1, Karoline Wallace, .2, Åsa Björketun, .3, Henrik Lindman, .3, Maria Andersson Ödman, .3, Kristian Bolin, .4.
1Pfizer AB, Stockholm, Sweden, 2Bristol Myers Squibb, Stockholm, Sweden, 3Uppsala University Hospital, Uppsala, Sweden, 4Centre for Health Economics, University of Gothenburg, Göteborg, Sweden.
1Pfizer AB, Stockholm, Sweden, 2Bristol Myers Squibb, Stockholm, Sweden, 3Uppsala University Hospital, Uppsala, Sweden, 4Centre for Health Economics, University of Gothenburg, Göteborg, Sweden.
OBJECTIVES: To address the growing demand for cancer care, Uppsala University Hospital, through a collaborative initiative between the public healthcare sector and private partners, has established a treatment clinic in the Gränby shopping center. The aim is to improve accessibility to cancer care and to relieve pressure on the hospital’s oncology treatment unit and hematology outpatient clinic. A health economic analysis has been conducted to evaluate the productivity and cost-effectiveness of the new Gränby clinic in comparison to existing cancer care services at Uppsala University Hospital.
METHODS: Productivity, defined as resource use in relation to output volume, was calculated over time for all cancer treatments, using the total number of treatments divided by available resources. The cost-effectiveness analysis was based on the assumption that treatment outcomes are equivalent regardless of location, as the only difference lies in the physical setting. Direct costs included facility rent, nurses’ time, and transportation of medical supplies to the Gränby clinic. Data was collected from the hospital’s electronic medical records as well as prospectively as time spent per treatment. The Gränby treatment clinic opened in January 2024 and has gradually increased its treatment volume. Comparison between the units were performed using data from Q1 2025 and the three previous years to compare over time.
RESULTS: The results show increased productivity in Q1 2025, both per nurse and per treatment chair, comparing to previous years. The direct cost per treatment per month in Q1 2025 was 718 SEK in Gränby compared to 1291 SEK at the hospital, where the largest part was attributed to facility costs.
CONCLUSIONS: Overall, the cost per treatment was about 50 percent lower at the treatment clinic in Gränby compared to the cost per treatment at the hospital. The results show that both productivity and cost-effectiveness have improved since the clinic opened.
METHODS: Productivity, defined as resource use in relation to output volume, was calculated over time for all cancer treatments, using the total number of treatments divided by available resources. The cost-effectiveness analysis was based on the assumption that treatment outcomes are equivalent regardless of location, as the only difference lies in the physical setting. Direct costs included facility rent, nurses’ time, and transportation of medical supplies to the Gränby clinic. Data was collected from the hospital’s electronic medical records as well as prospectively as time spent per treatment. The Gränby treatment clinic opened in January 2024 and has gradually increased its treatment volume. Comparison between the units were performed using data from Q1 2025 and the three previous years to compare over time.
RESULTS: The results show increased productivity in Q1 2025, both per nurse and per treatment chair, comparing to previous years. The direct cost per treatment per month in Q1 2025 was 718 SEK in Gränby compared to 1291 SEK at the hospital, where the largest part was attributed to facility costs.
CONCLUSIONS: Overall, the cost per treatment was about 50 percent lower at the treatment clinic in Gränby compared to the cost per treatment at the hospital. The results show that both productivity and cost-effectiveness have improved since the clinic opened.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE618
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology